3,819 results match your criteria Liver International[Journal]


Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease.

Liver Int 2019 Apr 22. Epub 2019 Apr 22.

Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

Background & Aims: Hepatitis C virus (HCV) infection has been known to cause various extrahepatic autoimmune disorders. The prevalence of platelet-associated immunoglobulin G (PA-IgG) has been high in patients with HCV infection. Because thrombocytopenia in HCV-related liver diseases is a notable problem, we performed prospective study on the effect of direct-acting antivirals (DAAs) treatment on PA-IgG and platelet count. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14120DOI Listing

Hepatitis C Virus Infection and Non-Hepatocellular Malignancies in the DAA Era: A Systematic Review and Meta-Analysis.

Liver Int 2019 Apr 15. Epub 2019 Apr 15.

Internal Medicine and Hepatology Unit, University of Salerno, Salerno, Italy.

Background And Aims: Direct antiviral agents have greatly improved therapeutic options for chronic hepatitis C. Indeed, former "difficult-to-treat" patients can now be treated and can achieve sustained response. HCV is associated with hepatocellular carcinoma and with B-cell non-Hodgkin lymphoma(B-NHL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14119DOI Listing
April 2019
1 Read

Prognostic Assessment using a New Substaging System for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma: A Nationwide Study.

Liver Int 2019 Apr 10. Epub 2019 Apr 10.

Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea.

Aim/background: Advanced hepatocellular carcinoma (HCC) [Barcelona Clinic Liver Cancer (BCLC) stage C] needs sub-classification to more accurately predict survival. This study aims to establish a substaging system of BCLC stage C HCC patients for accurate prognosis.

Methods: Data from 564 patients with newly diagnosed BCLC stage C HCC from three tertiary-care hospitals affiliated with the Korea University (training set) were assessed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14117DOI Listing

Accuracy of Imaging Methods for Steatohepatitis Diagnosis in Non-alcoholic Fatty Liver Disease Patients: A Systematic Review.

Liver Int 2019 Apr 10. Epub 2019 Apr 10.

Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia, Reggio Emilia, Italy.

Background & Aims: Non-invasive tests to diagnose non-alcoholic steatohepatitis (NASH) are urgently needed. This systematic review aims to evaluate imaging accuracy in diagnosing NASH among non-alcoholic fatty liver disease (NAFLD) patients, using liver biopsy as reference.

Methods: Eligible studies were systematic reviews and cross-sectional/cohort studies of NAFLD patients comparing imaging with histology, considering accuracy and/or associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14118DOI Listing
April 2019
4 Reads

Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study.

Liver Int 2019 Apr 9. Epub 2019 Apr 9.

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, The Netherlands.

Background & Aims: The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing, with concomitant high incidence of lipoprotein abnormalities. Cardiovascular disease (CVD) is the main cause of death in subjects with NAFLD and management of dyslipidemia is pivotal for prevention. We aimed to determine cardiovascular risk and indication for statin therapy in subjects with NAFLD. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.14116
Publisher Site
http://dx.doi.org/10.1111/liv.14116DOI Listing
April 2019
3 Reads

Long-Term Outcomes of Individualized Treatment Strategy in Treatment of Type I Budd-Chiari Syndrome in 456 patients.

Liver Int 2019 Apr 8. Epub 2019 Apr 8.

Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Aim: To evaluate individualized treatment strategy (ITS) and long-term outcomes of endovascular treatment of Budd-Chiari syndrome (BCS) with obstructed inferior vena cava (IVC) based on different degrees of hepatic vein (HV) involvement.

Methods: From January 2006 to June 2017, 456 consecutive patients with BCS with obstructed IVC underwent endovascular treatment with ITS. All patients received IVC recanalization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14114DOI Listing
April 2019
3 Reads
4.850 Impact Factor

Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib (LY2157299) in Advanced Hepatocellular Carcinoma.

Liver Int 2019 Apr 8. Epub 2019 Apr 8.

National Institute of Gastroenterology, Research Instituts "S. De Bellis" Research Hospital, Castellana Grotte, Bari, Italy.

Background And Aims: We assessed the activity of galunisertib, a small molecule inhibitor of the transforming growth factor beta (TGF-β1) receptor I, in second line patients with hepatocellular carcinoma (HCC) in two cohorts of baseline serum alpha fetoprotein (AFP).

Methods: Patients with advanced HCC who progressed on or were ineligible to receive sorafenib, Child-Pugh A/B7, and ECOG PS ≤1 were enrolled into Part A (AFP≥1.5x ULN) or Part B (AFP<1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14113DOI Listing
April 2019
1 Read

Cytokine Balance is Restored as Patient Reported Outcomes (PROs) Improve in Patients Recovering from Chronic Hepatitis C (CHC).

Liver Int 2019 Apr 8. Epub 2019 Apr 8.

Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, USA.

Background & Aims: Chronic hepatitis C (CHC) has a negative impact on patient reported outcomes (PROs). Although most CHC patients who achieve sustained virologic response (SVR) show an improvement in PRO scores, some continue to experience impairment in PROs. The aim was to investigate if serum biomarkers (selected neurotransmitters and cytokines) are associated with changes in PROs in CHC patients who achieve SVR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14115DOI Listing
April 2019
1 Read

Activation of the oncogenic miR-21-5p promotes HCV replication and steatosis induced by the viral core 3a protein.

Liver Int 2019 Apr 2. Epub 2019 Apr 2.

Faculty of Medicine, Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland.

Background & Aims: miR-21-5p is a potent oncogenic microRNA targeting many key tumour suppressors including phosphatase and tensin homolog (PTEN). We recently identified PTEN as a key factor modulated by hepatitis C virus (HCV) to promote virion egress. In hepatocytes, expression of HCV-3a core protein was sufficient to downregulate PTEN and to trigger lipid droplet accumulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14112DOI Listing

Hemobilia: historical overview, clinical update, and current practices.

Liver Int 2019 Apr 1. Epub 2019 Apr 1.

Division of Gastroenterology, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA, USA.

Hemobilia refers to macroscopic blood in the lumen of the biliary tree. It represents an uncommon, but important, cause of gastrointestinal bleeding and can have potentially lethal sequelae if not promptly recognized and treated. The earliest known reports of hemobilia date to the 17 century, but due to its relative rarity and challenges in diagnosis, it has historically not been well-studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14111DOI Listing
April 2019
7 Reads

Elevated urinary bisphenol A levels are associated with non-alcoholic fatty liver disease among adults in the United States.

Liver Int 2019 Mar 29. Epub 2019 Mar 29.

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA.

Background And Aims: The relationship between bisphenol A (BPA) and non-alcoholic fatty liver disease (NAFLD) is undefined. We studied the impact of BPA on NAFLD.

Methods: We performed a cross-sectional analysis of data from the National Health and Nutrition Examination Survey (NHANES) 2005-2014 among adults in the United States (US). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14110DOI Listing
March 2019
4.850 Impact Factor

Impacts of cigarette smoking on liver fibrosis and its regression under therapy in male patients with chronic hepatitis B.

Liver Int 2019 Mar 28. Epub 2019 Mar 28.

Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Background & Aims: The role of cigarette smoking in the development of chronic hepatitis B (CHB) remains poorly understood. We assessed the potential contributions of cigarette smoking to liver fibrosis and its regression after starting antiviral therapy in CHB patients.

Methods: In this cohort study, 2144 consecutive male CHB patients under no antiviral therapy were evaluated and 206 patients with significant liver fibrosis (≥F2) initiating antiviral therapy had longitudinal follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14108DOI Listing

Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis.

Liver Int 2019 Mar 28. Epub 2019 Mar 28.

Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Foggia, Italy.

Background & Aims: Several antibiotic treatments aiming to prevent spontaneous bacterial peritonitis (SBP) in cirrhotic patients with low-protein content in ascitic fluid have been tested; however, there are limited data on the comparative efficacy of these regimens. We assessed their comparative efficacy through a network meta-analysis and using GRADE criteria to appraise quality of evidence.

Methods: Through literature review through October 2018, we identified 10 randomized controlled trials comparing antibiotic treatments (norfloxacin, ciprofloxacin, trimethoprim/sulfamethoxazole and rifaximin) with each other or placebo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14109DOI Listing
March 2019
1 Read

Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids.

Liver Int 2019 Mar 28. Epub 2019 Mar 28.

Division of Gastroenterology (Liver Unit), University of Alberta, Edmonton, Alberta, Canada.

Background And Aims: Cirrhosis is associated with dysbiosis, but its functional consequences are still largely unknown. Short-chain fatty acids (SCFAs) account for physiological interactions between the gut microbiota and host. Our aim was to assess the impact of cirrhotic dysbiosis on the production of SCFAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14106DOI Listing
March 2019
2 Reads

Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients.

Liver Int 2019 Mar 27. Epub 2019 Mar 27.

Department of Medicine I, University of Bonn, Bonn, Germany.

Background: Severe hepatic steatosis shows a high prevalence and contributes to morbidity and mortality in human immunodeficiency virus (HIV) infected patients. Known risk factors include obesity, dyslipidaemia and features of metabolic syndrome. Fibroblast growth factor 21 (FGF-21) is involved with hepatic glucose and lipid metabolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14107DOI Listing
March 2019
1 Read

Growing muscle against cirrhosis: In the quest for models to revealing mechanisms.

Liver Int 2019 Apr;39(4):625-627

Laboratorio de Investigación en Hepatología y Gastroenterología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14032DOI Listing

HEV in pregnancy: Understanding the crucial role of steroid hormones.

Liver Int 2019 Apr;39(4):621-622

Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.13942DOI Listing

Don't forget to ask how mum and dad are doing.

Authors:
Stefano Romeo

Liver Int 2019 Apr;39(4):623-624

Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.13984DOI Listing

Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue.

Liver Int 2019 Mar 25. Epub 2019 Mar 25.

Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.

Background & Aims: It is unknown how concomitant hepatic steatosis affects disease progression in chronic hepatitis B (CHB). Adipokines such as fibroblast growth factor 21 (FGF21) and adipocyte fatty acid-binding protein (AFABP) have been associated with non-alcoholic fatty liver disease. We determined the significance of these metabolic markers in CHB-related liver injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14104DOI Listing
March 2019
1 Read

Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B.

Liver Int 2019 Mar 25. Epub 2019 Mar 25.

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada.

Background & Aims: The use of complementary and alternative medicine (CAM) in patients with chronic hepatitis B (CHB) can interact with antiviral treatment or influence health-seeking behaviour. We aimed to study the use of individual CAM modalities in CHB and explore determinants of use, particularly migration-related, socio-economic and clinical factors.

Methods: A total of 436 CHB outpatients who attended the Toronto Centre for Liver Disease in 2015-2016 were included in this cross-sectional study. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.14105
Publisher Site
http://dx.doi.org/10.1111/liv.14105DOI Listing
March 2019
9 Reads

The Tumor Microenvironment and Immune Milieu of Cholangiocarcinoma.

Liver Int 2019 Mar 25. Epub 2019 Mar 25.

Liver Center and Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT, USA.

Tumor microenvironment is a complex, multicellular functional compartment that, particularly when assembled as an abundant desmoplastic reaction, may profoundly affect the proliferative and invasive abilities of epithelial cancer cells. Tumor microenvironment comprises not only stromal cells, mainly cancer-associated fibroblasts, but also immune cells of both the innate and adaptive system (tumor-associated macrophages, neutrophils, natural killer cells, and T and B lymphocytes), and endothelial cells. This results in an intricate web of mutual communications regulated by an extensively remodeled extracellular matrix, where the tumor cells are centrally engaged. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.14098
Publisher Site
http://dx.doi.org/10.1111/liv.14098DOI Listing
March 2019
9 Reads

Signaling networks in cholangiocarcinoma: molecular pathogenesis, targeted therapies and drug resistance.

Liver Int 2019 Mar 23. Epub 2019 Mar 23.

Inserm, Univ Rennes, Inra, Institut NuMeCan (Nutrition Metabolisms and Cancer), UMR_S 1241, Rennes, France.

Cholangiocarcinoma (CCA) is a deadly disease. While surgery may attain cure in a minor fraction of cases, therapeutic options in either the adjuvant or advanced setting are limited. The possibility of advancing the efficacy of therapeutic approaches to CCA relies on understanding its molecular pathogenesis and developing rational therapies aimed at interfering with oncogenic signaling networks that drive and sustain cholangiocarcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14102DOI Listing
March 2019
1 Read

Neutrophil-to-lymphocyte ratio is a predictor of early graft dysfunction following living donor liver transplantation.

Liver Int 2019 Mar 23. Epub 2019 Mar 23.

Department of Anesthesiology and Pain Medicine, Laboratory for Cardiovascular Dynamics, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Republic of Korea.

Background & Aims: Early allograft dysfunction (EAD) is predictive of poor graft and patient survival following living donor liver transplantation (LDLT). Considering the impact of the inflammatory response on graft injury extent following LDLT, we investigated the association between neutrophil-to-lymphocyte ratio (NLR) and EAD, 1-year graft failure, and mortality following LDLT, and compared it to C-reactive protein (CRP), procalcitonin, platelet-to-lymphocyte ratio and the Glasgow prognostic score.

Methods: A total of 1960 consecutive adult LDLT recipients (1531/429 as development/validation cohort) were retrospectively evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14103DOI Listing

Medical treatment for cholangiocarcinoma.

Liver Int 2019 Mar 20. Epub 2019 Mar 20.

Division of Cancer Sciences, University of Manchester, Manchester, UK.

Most of patients with cholangiocarcinoma (CCA) present with advanced (inoperable or metastatic) disease, and relapse rates are high in those undergoing potentially-curative resection. Previous treatment nihilism of patients with advanced disease has been replaced by active clinical research with the advent of randomized clinical trials (RCTs) and a much greater effort at understanding molecular mechanisms underpinning CCA. Three RCTs have recently been reported evaluating adjuvant chemotherapy following curative resection; only one of these has the potential to change practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14100DOI Listing
March 2019
4 Reads

Anatomical, histomorphological, and molecular classification of cholangiocarcinoma.

Liver Int 2019 Mar 18. Epub 2019 Mar 18.

Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome "Foro Italico", Rome, Italy.

Cholangiocarcinoma constitutes a heterogeneous group of malignancies that can emerge at any point of the biliary tree. Cholangiocarcinoma is classified into intrahepatic, perihilar and distal based on its anatomical location. Histologically, conventional perihilar/distal cholangiocarcinomas are mucin-producing adenocarcinomas or papillary tumors; intrahepatic cholangiocarcinomas are more heterogeneous and can be sub-classified according to the level or size of the displayed bile duct. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14093DOI Listing
March 2019
1 Read

Characterization of the circulating microbiome in acute-on-chronic liver failure associated with hepatitis B.

Liver Int 2019 Mar 13. Epub 2019 Mar 13.

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Background: Patients with hepatitis B-related acute-on-chronic liver failure (HB-ACLF) may have an increased circulating microbial burden. This study aimed to assess circulating microbial load and composition and to explore the association between the circulating microbiome and both systemic inflammation (SI) and clinical outcome in HB-ACLF.

Methods: Plasma from 50 HB-ACLF patients, 23 healthy controls and 25 patients with compensated liver cirrhosis (C-LC) was analysed for chemokines/cytokines and bacterial DNA and further analysed by 16S rDNApyrosequencing. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/liv.14097
Publisher Site
http://dx.doi.org/10.1111/liv.14097DOI Listing
March 2019
4 Reads
4.850 Impact Factor

Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma.

Liver Int 2019 Mar 9. Epub 2019 Mar 9.

Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy.

Human cholangiocarcinoma (CCA) is an aggressive tumour entity arising from the biliary tree, whose molecular pathogenesis remains largely undeciphered. Over the last decade, the advent of high-throughput and cell-based techniques has significantly increased our knowledge on the molecular mechanisms underlying this disease while, at the same time, unravelling CCA complexity. In particular, it becomes clear that CCA displays pronounced inter- and intra-tumoural heterogeneity, which is presumably the consequence of the interplay between distinct tissues and cells of origin, the underlying diseases, and the associated molecular alterations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14094DOI Listing
March 2019
10 Reads

Cholangiocarcinoma: Epidemiology and risk factors.

Liver Int 2019 Mar 9. Epub 2019 Mar 9.

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

Cholangiocarcinoma (CCA) is a heterogeneous disease arising from a complex interaction between host-specific genetic background and multiple risk factors. Globally, CCA incidence rates exhibit geographical variation, with much higher incidence in parts of the Eastern world compared to the West. These differences are likely to reflect differences in geographical risk factors as well as genetic determinants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14095DOI Listing
March 2019
2 Reads

Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease.

Liver Int 2019 Mar 9. Epub 2019 Mar 9.

Division of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Modena, Italy.

Background & Aims: Hyperferritinemia, with or without increased hepatic iron, represents a common finding in non-alcoholic fatty liver disease (NAFLD). However, it is unclear whether it reflects hepatic inflammation or true iron-overload and, in case the latter is confirmed, whether this influences disease progression. We therefore explored the association between serum ferritin, degree and pattern of hepatic iron deposition and liver disease severity in patients with NAFLD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14096DOI Listing
March 2019
1 Read

The relationship between coronary artery disease and cardiovascular events early after liver transplantation.

Liver Int 2019 Mar 8. Epub 2019 Mar 8.

Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.

Background & Aims: Cardiovascular complications are major contributors to mortality at liver transplantation (LT). However, the impact of coronary artery disease (CAD) on these complications is not well-understood as the literature is limited by non-invasive assessment of CAD, which is suboptimal in patients with cirrhosis. Thus, the current study evaluated cardiovascular events at LT stratified according to the presence and severity of CAD quantified on coronary angiography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14092DOI Listing
March 2019
2 Reads

Surgery For Cholangiocarcinoma.

Liver Int 2019 Mar 6. Epub 2019 Mar 6.

Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Surgical resection is the only potentially curative treatment for patients with cholangiocarcinoma. For both perihilar cholangiocarcinoma (pCCA) and intrahepatic cholangiocarcinoma (iCCA), 5-year overall survival of about 30% has been reported in large series. This review addresses several challenges in surgical management of cholangiocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14089DOI Listing
March 2019
2 Reads

Milestones in the discovery of Budd-Chiari syndrome.

Liver Int 2019 Mar 6. Epub 2019 Mar 6.

Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.

In 1845, George Budd published a brief report regarding three patients who developed an obstruction of the hepatic veins. The condition has never been reported before, and was related to sepsis and alcoholism. Fifty-three years later, Hans Chiari postulated that syphilis was causing the obstruction of the hepatic veins, and enriched the debate with clinical and pathological correlations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14088DOI Listing
March 2019
6 Reads

Diagnostic and prognostic biomarkers in cholangiocarcinoma.

Liver Int 2019 Mar 6. Epub 2019 Mar 6.

Centre for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.

The high mortality rate of cholangiocarcinoma (CCA) is due, in part, to the lack of non-invasive approaches able to accurately detect this silent tumour at early stages, when therapeutic options can be potentially curative or may at least increase the overall survival of patients. The fact that the majority of CCA tumours are not linked to any known aetiological factor highly compromises the monitoring of patients at risk for tumour development and also their early diagnosis. Combination of clinical/biochemical features, imaging techniques and analysis of non-specific tumour biomarkers in serum are commonly used to help in the diagnosis of CCA, but tumour biopsy is usually required to confirm the diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14090DOI Listing
March 2019
2 Reads

Ischaemia reperfusion injury in liver transplantation: Cellular and molecular mechanisms.

Liver Int 2019 May 2;39(5):788-801. Epub 2019 Apr 2.

Department of Anesthesia, McGovern Medical School at UT Health, Houston, Texas.

Liver disease causing end organ failure is a growing cause of mortality. In most cases, the only therapy is liver transplantation. However, liver transplantation is a complex undertaking and its success is dependent on a number of factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14091DOI Listing
May 2019
1 Read

Clinical presentation, diagnosis and staging of cholangiocarcinoma.

Liver Int 2019 Mar 4. Epub 2019 Mar 4.

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

Cholangiocarcinoma (CCA) is a heterogeneous group of tumours, derived from cells of the biliary tree, which represent the second most frequent primary liver tumour. According to the most recent classifications, CCA can be subdivided into intrahepatic (iCCA) and extrahepatic (eCCA) which include perihilar (pCCA) and distal (dCCA) CCA. CCA are usually identified at advanced stages, when the primary tumour grows enough to produce a large liver mass or when jaundice has developed because of biliary tree obstruction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14086DOI Listing
March 2019
7 Reads

Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.

Liver Int 2019 Apr 7. Epub 2019 Apr 7.

Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden.

Background And Aims: Non-alcoholic fatty liver disease (NAFLD) is a growing cause of hepatocellular carcinoma (HCC). In NAFLD, HCC occurs more commonly in the absence of cirrhosis compared with other liver diseases; yet, patients with non-cirrhotic NAFLD-HCC are poorly characterized. Here, we characterized a large cohort of HCC cases and assessed the outcomes of patients with non-cirrhotic NAFLD-HCC. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/liv.14087
Publisher Site
http://dx.doi.org/10.1111/liv.14087DOI Listing
April 2019
7 Reads
4.850 Impact Factor

Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?

Liver Int 2019 Mar 4. Epub 2019 Mar 4.

Department of Health and Medical Sciences, Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen N, Denmark.

The complexity of cholangiocarcinoma (CCA) cellularity and the molecular perturbation mechanisms that underlie the diversity of growth patterns of this malignancy remain a clinical concern. Tumours of the biliary system display significant intrinsic chemoresistance, caused by significant stromal involvement and genome-wide tumour heterogeneity, hampering disease remission and palliation as well as promoting the metastatic behaviour. It is crucial to advance our present understanding of the risk and molecular pathogenesis of CCA. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/liv.14085
Publisher Site
http://dx.doi.org/10.1111/liv.14085DOI Listing
March 2019
9 Reads
4.850 Impact Factor

Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failure.

Liver Int 2019 Mar 1. Epub 2019 Mar 1.

Gastroenterology Division (Liver Unit), University of Alberta Hospital, Edmonton, AB, Canada.

Background And Aims: Patients with acute-on-chronic liver failure (ACLF) have high mortality rates. Most prognostic scores were not developed for the intensive care unit (ICU) setting. We aimed to improve risk stratification for patients with ACLF in the ICU. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/liv.14083
Publisher Site
http://dx.doi.org/10.1111/liv.14083DOI Listing
March 2019
4 Reads

MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.

Liver Int 2019 Mar 1. Epub 2019 Mar 1.

Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Introduction: MACK-3 (combination of hoMa, Ast and CK18) was reported to be a good biomarker for the diagnosis of fibrotic non-alcoholic steatohepatitis (NASH). However, there is no external validation to date.

Aim: To evaluate the accuracy of MACK-3 for the diagnosis of fibrotic NASH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14084DOI Listing
March 2019
2 Reads

Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country.

Liver Int 2019 May 25;39(5):985-994. Epub 2019 Mar 25.

Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Background & Aims: As surrogate markers for autoimmune hepatitis (AIH), serum alanine aminotransferase (ALT) and immunoglobulin G (IgG) are convenient to measure under immunosuppression. However, the long-term prognosis of patients who achieve complete biochemical remission (CBR) in comparison with patients who achieve only biochemical remission (BR) is uncertain.

Methods: A total of 291 patients (89. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14082DOI Listing
May 2019
3 Reads

Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients.

Liver Int 2019 Feb 27. Epub 2019 Feb 27.

Division of Gastroenterology and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Background & Aims: Cardiovascular disease (CVD) is the leading cause of death among non-alcoholic steatohepatitis (NASH) patients and a major source of post-transplant mortality. We sought to examine the effect of comorbidities on listing for orthotopic liver transplant (OLT) in NASH patients.

Methods: In this retrospective cohort study, we included all patients (n = 955) referred to Beth Israel Deaconess Medical Center for OLT between January 2002 and September 2011 and followed their outcomes through March 2018. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/liv.14080
Publisher Site
http://dx.doi.org/10.1111/liv.14080DOI Listing
February 2019
6 Reads

Outcomes of in-hospital cardiopulmonary resuscitation for patients with end-stage liver disease.

Liver Int 2019 Feb 27. Epub 2019 Feb 27.

Division of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.

Background And Aims: There have been improving survival trends after in-hospital cardiac arrest for the general population, but there is limited information on the outcomes of hospitalized patients with end-stage liver disease (ESLD) who undergo cardiopulmonary resuscitation (CPR). We aimed to examine survival to hospital discharge after receipt of in-hospital CPR in patients with ESLD using a nationally representative sample.

Methods: We used the Nationwide Inpatient Sample database from 2006 to 2014 to identify adult patients who underwent in-hospital CPR. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/liv.14079
Publisher Site
http://dx.doi.org/10.1111/liv.14079DOI Listing
February 2019
12 Reads

Racial disparities in presentation and outcomes of paediatric autoimmune hepatitis.

Liver Int 2019 May 19;39(5):976-984. Epub 2019 Mar 19.

Transplant Services, Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia.

Background & Aims: Most studies on autoimmune hepatitis (AIH) in children are in predominantly Caucasian cohorts. Paediatric AIH in African Americans (AA) is understudied, with a dearth of clinical predictors of outcome, often leading to serious complications and even mortality. The aim of the study was to define disease presentation, progression, response to therapy and outcomes in paediatric AIH in a well-defined, large, single centre, demographically diverse population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14081DOI Listing
May 2019
1 Read

Direct-acting antivirals and the risk of hepatocellular carcinoma: The end of a polemic?

Liver Int 2019 Mar;39(3):446-447

Institut National de la santé et de la Recherche Médicale, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14029DOI Listing

The rise of Clostridioides difficile infections and fall of associated mortality in hospitalized advanced cirrhotics.

Liver Int 2019 Feb 21. Epub 2019 Feb 21.

Division of Gastroenterology and Hepatology, Weill Cornell Medicine - New York-Presbyterian Hospital, New York, New York.

Background & Aims: Cirrhotics are at increased risk of Clostridioides difficile infection (CDI) and its associated high morbidity and mortality. However, the impact of CDI in cirrhotics over time remains unclear. This study analyses prevalence and mortality in CDI in hospitalized patients with advanced cirrhosis over 15 years and identifies trends. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14077DOI Listing
February 2019
1 Read

Occult hepatitis B virus and surface antigen mutant infection in healthy vaccinated cohorts and children with various forms of hepatitis and multiple transfusions.

Liver Int 2019 Feb 21. Epub 2019 Feb 21.

Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.

Background And Aims: Despite the success of universal infant immunization initiated in Taiwan in 1984, occult hepatitis B virus infection (OBI) and circulating surface antigen mutants remain potential obstacles for eventual eradication of HBV infection.

Methods: From 3299 apparently healthy, neonatally-vaccinated subjects (<30 years of age ) enrolled during 2014 serosurvey, we recruited all HBsAg-positive (n = 17), all HBsAg-negative but anti-HBc-positive (n = 132) and randomly selected HBsAg-negative and anti-HBc-negative subjects (n = 411). These recruited subjects and 81 HBsAg-negative children with various forms of hepatitis and multiple transfusions were analysed for serum HBV DNA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14076DOI Listing
February 2019
1 Read

The impact of age and ageing on hepatocarcinoma surgery: Short- and long-term outcomes in a multicentre propensity-matched cohort.

Liver Int 2019 May 26;39(5):894-904. Epub 2019 Mar 26.

School of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy.

Background: Management of malignancy in elderly patients is challenging. We aimed to assess the impact of age and ageing on overall survival (OS), recurrence-free survival (RFS), tumour-specific survival (TSS) and potential years of life lost (PYLL) after surgery for hepatocarcinoma (HCC).

Methods: Consecutive patients treated for HCC between 2005 and 2015 were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14075DOI Listing
May 2019
4.850 Impact Factor

The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: A retrospective cohort study.

Liver Int 2019 May 19;39(5):905-913. Epub 2019 Mar 19.

Department of Hepatopancreatobiliary Surgery and Liver Transplantation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Background & Aims: Hepatocellular adenomas (HCA) are rare, hormone-driven, benign liver tumours. HCA >50 mm are associated with haemorrhage and malignant transformation. Guidelines recommend cessation of oral contraceptive pills (OCP) for size reduction; however, it is currently unknown how HCA respond to cessation of OCP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14074DOI Listing
May 2019
4 Reads

Molecular epidemiology of acute HCV infection in HIV-positive patients from Hong Kong, Taipei, Tokyo.

Liver Int 2019 Feb 16. Epub 2019 Feb 16.

Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Background: Acute hepatitis C virus (HCV) infections have been increasingly reported among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) in the Asia-Pacific region. It remains unknown whether international network of HCV transmission has occurred in this region.

Methods: HIV-positive patients with acute HCV infection, defined as HCV seroconversion within a year or documented acute hepatitis with seroconversion, diagnosed in Hong Kong, Taipei and Tokyo during 2010-2016 were included in this molecular epidemiology study. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/liv.14073
Publisher Site
http://dx.doi.org/10.1111/liv.14073DOI Listing
February 2019
8 Reads

Long-term outcomes of patients with hepatitis B virus-related acute on chronic liver failure: An observational cohort study.

Liver Int 2019 May 8;39(5):854-860. Epub 2019 Mar 8.

Liver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Background And Aims: The long-term outcomes of patients with hepatitis B virus-related acute on chronic liver failure (HBV-ACLF) remain unclear. The main aim of the study was to compare the 5-year survival rate and incidence rate of hepatocellular carcinoma (HCC) between patients with HBV-ACLF and HBV-cirrhosis.

Methods: Clinical data of patients with ACLF, compensated cirrhosis and decompensated cirrhosis who survived more than 3 months after diagnosis were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14072DOI Listing
May 2019
1 Read